Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Oligomycin and the Logic of Mitochondrial ATP Flux
2026-11-19
Oligomycin A links ATP synthase activity to mitochondrial respiration, nucleotide exchange, glycolytic compensation, and context-dependent cell death. Evidence from an ANT isoform study refines this model by showing that several human ADP/ATP carriers can support respiration redundantly, while their coupling to ATP synthase remains mechanistically important.
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-11-18
Boyle and colleagues used genetic, ligand-stimulation, pharmacological, cellular, and database-based evidence to examine how CCR7 signaling intersects with Notch1 in stem-like cells from MMTV-PyMT mammary tumors. The findings support functional pathway crosstalk involving Notch1 cleavage and Hes1-associated signaling, while remaining preclinical and model-specific.
Annexin V Signals in the ENO1–Cardiac Repair Axis
2026-11-18
Annexin V fluorescence provides a downstream measure of cell-surface phosphatidylserine exposure, helping contextualize cardiomyocyte injury in a study of ENO1-driven macrophage metabolism after myocardial infarction. The evidence supports an ENO1–lactate–KLF4 pathway, while also showing why an apoptosis assay cannot by itself establish irreversible cell death or therapeutic causality.
What Relutrigine’s Channel Data Actually Show
2026-11-17
Relutrigine (PRAX-562) is documented as a use-dependent inhibitor of persistent sodium currents. Its reported IC50 values differ between an activated Nav1.5 context and the SCN8A N1768D variant, supporting a context-specific molecular interpretation rather than direct proof of seizure control or clinical benefit.
What Can NSI-189 Identity Establish?
2026-11-17
NSI-189’s documented structure supports framing it as a nicotinamide derivative for neurogenesis and cognition research, but it does not identify a molecular target or prove a behavioral or disease effect. A sound interpretation separates chemical identity, cellular readouts, brain function, and translational claims.
IRP2, TFEB, and Macrophage Defense
2026-11-16
A 2024 mouse study links myeloid IRP2 loss to impaired lysosomal antimicrobial function through HIF2α, lactate, and TFEB mislocalization. The evidence separates defective intracellular bacterial clearance from phagocytic uptake and connects the mouse phenotype with observations in inflammatory bowel disease tissue, while leaving important questions about cell-type specificity and clinical causality.
How Maytansine Connects Tubulin to Metaphase Arrest
2026-11-15
Maytansine, also known as NSC 153858, is described as a tubulin-binding mitotic arrest agent. This article explains how disrupted microtubule dynamics can lead to metaphase arrest and reduced tumor-cell proliferation in vitro, while distinguishing those findings from antibody–drug conjugate performance or clinical benefit.
How to Interpret Azomycin Antimicrobial Readouts
2026-11-14
Azomycin’s nitroimidazole structure supports a class-level explanation for redox-dependent antimicrobial activity, but chemical identity, molecular injury and microbial inhibition are different levels of evidence. This article explains how to connect those levels without treating product documentation as proof of product-specific potency or clinical value.
What Relutrigine’s Sodium-Channel Data Show
2026-11-13
Relutrigine (PRAX-562) is documented as a use-dependent inhibitor of persistent sodium currents. Its reported IC50 values differ between an activated Nav1.5 context and the SCN8A N1768D variant, supporting a context-specific mechanism relevant to neuronal excitability and sodium channelopathies research, but not by themselves establishing efficacy in a seizure disorder model or clinical benefit.
How Pemetrexed Disrupts Nucleotide Synthesis
2026-11-13
Pemetrexed is described as a multi-target antifolate whose intracellular polyglutamated forms interfere with several folate-dependent enzymes. Understanding the distinction between enzyme inhibition, nucleotide imbalance, and cellular proliferation helps define what a mechanistic result can—and cannot—show.
What NSI-189 Identity Can Tell Us
2026-11-12
NSI-189 is documented as a nicotinamide-derived small molecule associated with neurogenesis and nootropic research. Its chemical identity can frame mechanistic questions, but it does not by itself establish a molecular target, cognitive effect, disease-model activity, or safety profile.
Why MCT1 Blockade Can Raise Tumor Lactate
2026-11-12
AZD 3965 illustrates why blocking lactate transport can increase measured intratumoral lactate while suppressing tumor growth. The documented pattern is consistent with a context-dependent metabolic vulnerability in selected hypoxic small-cell lung cancer models, not a universal cancer effect.
ACE2–MasR–Sirt1 Signaling in Septic Hearts
2026-11-11
A mouse study examined whether pharmacological ACE2 activation or inhibition changes sepsis-induced cardiomyopathy. The reported findings connect ACE2 activation with improved cardiac phenotypes and MasR–Sirt1-associated mitochondrial biogenesis, while the model and pharmacological design limit direct extrapolation to human disease or definitive pathway causality.
How PRIMA-1MET Evidence Connects p53 to Apoptosis
2026-11-11
PRIMA-1MET, also known as APR-246, is described as a mutant-p53 reactivator. Its proposed mechanism links altered p53 binding with transcriptional changes, caspase-2 activation, mitochondria-mediated apoptosis, and reported tumor-growth effects. These findings represent different levels of evidence and should not be treated as interchangeable proof of clinical benefit.
How to Interpret AZD5462 in Cardiac Fibrosis
2026-11-10
AZD5462 is documented as a human relaxin homologous receptor modulator associated with RXFP1. Its scientific value lies in connecting receptor-level signaling with inflammation, extracellular-matrix remodeling, tissue fibrosis, and cardiac function without treating any single readout as proof of whole-organ benefit.